Compare IDEXX Laboratories, Inc. (IDXX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs AT&T Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while AT&T Inc. trades at $22.18 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 4.2× IDEXX Laboratories, Inc.'s market cap, and AT&T Inc. pays a 4.46% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and AT&T Inc. for 118 Days on average.
| IDXX | T | |
|---|---|---|
Market Cap | $40.43B | $170.42B |
Volume | 692,164 | 50,780,036 |
Sector | Health | Media |
52-Week High | $766.68 | $29.10 |
52-Week Low | $504.70 | $20.49 |
Typical Hold Time | 46 Days | 118 Days |
Enterprise Value | $41.32B | $315.74B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
AT&T (T) trades at $24.885, up 1.68% today, with a bullish technical signal overall despite mixed moving averages and oscillators. The company shows strong fundamentals with a P/E of 8.21, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights a $3 billion fiber deal with Corning and a joint venture with T-Mobile and Verizon to expand coverage.
The outlook is positive with a consensus price target of $27.50, offering potential upside. Key risks include high debt levels and competitive pressures. The stock presents a value opportunity with a solid dividend, but investors should monitor debt management and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
